1Q Revenues: $16.1 billion (flat)
1Q Earnings: $3.9 billion (+12%)
Comments: Pharma sales were $6.3 billion, up 1%, with a slight negative impact from currency rates. Consumer sales dropped 2% to $3.6 billion, as the company continues to struggle with product shortages generated by its quality problems. Remicade sales were up 18% to $1.5 billion and Stelara sales rose 33% to $221 million, but Levaquin sales plummeted 93% from $434 million to $29 million. Doxil sales also collapsed, dropping from $139 million to $24 million. Velcade sales rose 26% to $353 million.